Delayed and Unreported Drug-Susceptibility Testing Results in the US National Tuberculosis Surveillance System, 1993-2014

Overview

Journal Public Health Rep

Publisher Sage Publications

Specialty Public Health

Date 2017 Jun 7

PMID 28586626

Authors

Jefferson Michael Jones

Lori R Armstrong

Affiliations

Soon will be listed here.

Abstract

Objectives: Drug-susceptibility testing (DST) of Mycobacterium tuberculosis is necessary for identifying drug-resistant tuberculosis, administering effective treatment regimens, and preventing the spread of drug-resistant tuberculosis. DST is recommended for all culture-confirmed cases of tuberculosis. We examined trends in delayed and unreported DST results in the Centers for Disease Control and Prevention's National Tuberculosis Surveillance System.

Methods: We analyzed culture-confirmed tuberculosis cases reported to the National Tuberculosis Surveillance System during 1993-2014 for annual trends in initial DST reporting for first-line antituberculosis drugs and trends in on-time, delayed, and unreported results. We defined on-time reporting as DST results received during the same calendar year in which the patient's case was reported or ≤4 months after the calendar year ended and delayed reporting as DST results received after the calendar year. We compared cases with on-time, delayed, and unreported DST results by patient and tuberculosis program characteristics.

Results: The proportion of cases with reported results for all first-line antituberculosis drugs increased during 1993-2011. Reporting of pyrazinamide results was lower than reporting of other drugs. However, during 2000-2012, of 134 787 tuberculosis cases reported to the National Tuberculosis Surveillance System, reporting was on time for 125 855 (93.4%) cases, delayed for 5332 (4.0%) cases, and unreported for 3600 (2.7%) cases.

Conclusions: Despite increases in the proportion of cases with on-time DST results, delayed and unreported results persisted. Carefully assessing causes for delayed and unreported DST results should lead to more timely reporting of drug-resistant tuberculosis.

References

Tyrrell F, Budnick G, Elliott T, Gillim-Ross L, Hildred M, Mahlmeister P . Probability of negative mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercial-broth-based culture systems. J Clin Microbiol. 2012; 50(10):3275-82. PMC: 3457445. DOI: 10.1128/JCM.01225-12. View

Tattevin P, Casalino E, Fleury L, Egmann G, Ruel M, Bouvet E . The validity of medical history, classic symptoms, and chest radiographs in predicting pulmonary tuberculosis: derivation of a pulmonary tuberculosis prediction model. Chest. 1999; 115(5):1248-53. DOI: 10.1378/chest.115.5.1248. View

Blumberg H, Burman W, Chaisson R, Daley C, Etkind S, Friedman L . American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167(4):603-62. DOI: 10.1164/rccm.167.4.603. View

Wallace R, Kammerer J, Iademarco M, Althomsons S, Winston C, Navin T . Increasing proportions of advanced pulmonary tuberculosis reported in the United States: are delays in diagnosis on the rise?. Am J Respir Crit Care Med. 2009; 180(10):1016-22. DOI: 10.1164/rccm.200901-0059OC. View

DeSalvo K, OCarroll P, Koo D, Auerbach J, Monroe J . Public Health 3.0: Time for an Upgrade. Am J Public Health. 2016; 106(4):621-2. PMC: 4816012. DOI: 10.2105/AJPH.2016.303063. View

Marks S, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S . Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis. 2014; 20(5):812-21. PMC: 4012799. DOI: 10.3201/eid2005.131037. View

. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009; 58(1):7-10. View

. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep. 2009; 58(RR-3):1-43. View

Siddiqi S, Ahmed A, Asif S, Behera D, Javaid M, Jani J . Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the Bactec MGIT 960 system: a multicenter study. J Clin Microbiol. 2011; 50(2):435-40. PMC: 3264138. DOI: 10.1128/JCM.05188-11. View

10.

Lagrange-Xelot M, Porcher R, Gallien S, Wargnier A, Pavie J, De Castro N . Prevalence and clinical predictors of pulmonary tuberculosis among isolated inpatients: a prospective study. Clin Microbiol Infect. 2010; 17(4):610-4. DOI: 10.1111/j.1469-0691.2010.03259.x. View

11.

Cain K, Benoit S, Winston C, Mac Kenzie W . Tuberculosis among foreign-born persons in the United States. JAMA. 2008; 300(4):405-12. DOI: 10.1001/jama.300.4.405. View

12.

Kim H, Fay M, Feuer E, Midthune D . Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19(3):335-51. DOI: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z. View

13.

Pawlowski A, Jansson M, Skold M, Rottenberg M, Kallenius G . Tuberculosis and HIV co-infection. PLoS Pathog. 2012; 8(2):e1002464. PMC: 3280977. DOI: 10.1371/journal.ppat.1002464. View

14.

. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1994; 43(RR-13):1-132. View

15.

. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This.... Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1376-95. DOI: 10.1164/ajrccm.161.4.16141. View